The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design
share
Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are driving the substantial levels of non-adherence observed in this population. Data sources and study setting We use data from the TriNetX Diamond Network (TDN) United States database for the period from first availability in 2011 through the end of patent exclusivity following the introduction of generic imatinib in early 2016. Study design We implement a fuzzy regression discontinuity design to separately estimate the effect of Medicare Part D enrollment at age 65 on adherence and OOP in newly-diagnosed CML patients initiating branded imatinib. The corresponding price elasticity of demand (PED) is estimated and results are assessed across a variety of specifications and robustness checks. Data collection/extraction methods Data from eligible patients following the application of inclusion and exclusion criteria were analyzed. Principal findings Our analysis suggests that there is a significant increase in initial OOP of 232 (95 individuals that enrolled in Part D due to expanded eligibility at age 65. The relatively smaller and non-significant decrease in adherence of only 6 percentage points (95 -0.056, 0.015). Conclusion This study provides evidence regarding the financial impact of coinsurance-based benefit designs on Medicare-age patients with CML initiating branded imatinib. Results indicate that factors besides high OOP are driving the substantial non-adherence observed in this population and add to the growing literature on PED for specialty drugs.
READ FULL TEXT